Abstract
Among the seven classes of serotonin (5-hydroxytryptamine, 5-HT) receptorswhich have been identified to date, the 5-HT1 class is comprised of five receptor types,with the 5-HT1A, 5-HT1B and 5-HT1Dcharacterized by a high affinity for 5-carboxamidotryptamine,the 5-HT1E and 5-HT1F characterized by a low affinity for this syntheticagonist, and all five having a nanomolar affinity for the endogenous indolamine ligand.The genes encoding 5-HT1 receptors have been cloned in both human and rodents,allowing the demonstration that they all belong to the G-protein-coupled receptor superfamilywith the characteristic7hydrophobic(transmembrane) domain-containing amino acid sequence. All the5-HT1 receptor types actually interact with Gαi / Gαoproteins to inhibit adenylyl cyclase and modulate ioniceffectors, i.e. potassium and / or calcium channels. Probes derived from the knowledge of amino acid sequence ofthe receptor proteins and of nucleotide sequence of their encoding mRNAs allowed the mapping of all the 5-HT1 receptor types in the central nervous system and other tissues. For the last twenty years, bothpharmacological investigations with selective agonists and antagonists and phenotypical characterization ofknock-out mice have been especially informative regarding the physiological implications of 5-HT1 receptortypes. This research ends notably with the development of triptans, whose agonist activity at 5-HT1B, 5-HT1Dand 5-HT1F receptors underlies their remarkable efficacy as antimigraine drugs. Clear-cut evidence of theimplication of 5-HT1 receptors in anxiety- and depression-like behaviours and cognitive performances inrodents should hopefully promote research toward development of novel drugs with therapeutic potential inpsychopathological and dementia-related diseases.
Keywords: 5-HT1B, bothpharmacological, anxiety
Current Drug Targets - CNS & Neurological Disorders
Title: 5-HT1 Receptors
Volume: 3 Issue: 1
Author(s): Laurence Lanfumey and Michel Hamon
Affiliation:
Keywords: 5-HT1B, bothpharmacological, anxiety
Abstract: Among the seven classes of serotonin (5-hydroxytryptamine, 5-HT) receptorswhich have been identified to date, the 5-HT1 class is comprised of five receptor types,with the 5-HT1A, 5-HT1B and 5-HT1Dcharacterized by a high affinity for 5-carboxamidotryptamine,the 5-HT1E and 5-HT1F characterized by a low affinity for this syntheticagonist, and all five having a nanomolar affinity for the endogenous indolamine ligand.The genes encoding 5-HT1 receptors have been cloned in both human and rodents,allowing the demonstration that they all belong to the G-protein-coupled receptor superfamilywith the characteristic7hydrophobic(transmembrane) domain-containing amino acid sequence. All the5-HT1 receptor types actually interact with Gαi / Gαoproteins to inhibit adenylyl cyclase and modulate ioniceffectors, i.e. potassium and / or calcium channels. Probes derived from the knowledge of amino acid sequence ofthe receptor proteins and of nucleotide sequence of their encoding mRNAs allowed the mapping of all the 5-HT1 receptor types in the central nervous system and other tissues. For the last twenty years, bothpharmacological investigations with selective agonists and antagonists and phenotypical characterization ofknock-out mice have been especially informative regarding the physiological implications of 5-HT1 receptortypes. This research ends notably with the development of triptans, whose agonist activity at 5-HT1B, 5-HT1Dand 5-HT1F receptors underlies their remarkable efficacy as antimigraine drugs. Clear-cut evidence of theimplication of 5-HT1 receptors in anxiety- and depression-like behaviours and cognitive performances inrodents should hopefully promote research toward development of novel drugs with therapeutic potential inpsychopathological and dementia-related diseases.
Export Options
About this article
Cite this article as:
Lanfumey Laurence and Hamon Michel, 5-HT1 Receptors, Current Drug Targets - CNS & Neurological Disorders 2004; 3 (1) . https://dx.doi.org/10.2174/1568007043482570
DOI https://dx.doi.org/10.2174/1568007043482570 |
Print ISSN 1568-007X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-007X |
Related Articles
-
Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy Giant Cell Arteritis - Beyond the Headache
Current Rheumatology Reviews Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
Current Drug Metabolism The Neuroprotective Role of Vesicular Monoamine Transporter 2 in Neurodegenerative Diseases
Medicinal Chemistry Multivariate Optimization Model in a Partial Least Squares-1 Method for Simultaneous Determination of Dorzolamide Hydrochloride and Timolol Maleate in Eye Drops
Current Pharmaceutical Analysis Possible Usefulness of Growth Hormone/Insulin-like Growth Factor-I Axis in Alzheimer’s Disease Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets Physical Inactivity is Liable to the Increased Cardiovascular Risk and Impaired Cognitive Profile
Current Alzheimer Research Synthesis, Molecular Docking, and Biological Evaluation of Benzimidazole Derivatives as Selective Butyrylcholinesterase Inhibitors
Current Alzheimer Research 5-HT3 Receptors
Current Drug Targets - CNS & Neurological Disorders Subject Index To Volume 3
Vascular Disease Prevention (Discontinued) Cerebral Angiogenesis and Expression of Angiogenic Factors in Aging Rats after Exercise
Current Neurovascular Research Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research Geniposide Attenuates Mitochondrial Dysfunction and Memory Deficits in APP/PS1 Transgenic Mice
Current Alzheimer Research COVID-19-associated Coagulopathy and Thromboembolism: Determination of Their Patterns and Risk Factors as Predictors of Mortality Among Severe COVID-19 Patients
Current Vascular Pharmacology Association between <i>Toxoplasma gondii</i> Infection and Headache: A Systematic Review and Meta-Analysis
Infectious Disorders - Drug Targets Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists
Current Topics in Medicinal Chemistry Diabetes Mellitus: Novel Insights, Analysis and Interpretation of Pathophysiology and Complications Management with Imidazole-Containing Peptidomimetic Antioxidants
Recent Patents on Drug Delivery & Formulation Lipid Based Nanocarriers for Delivery of Anti-HIV Drugs: A Mini Review
Nanoscience & Nanotechnology-Asia Antiretroviral Therapy Regimens for Neuro-AIDS
Current Drug Targets - Infectious Disorders Novel Kynurenic Acid Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and Pharmaceutical Design
Current Pharmaceutical Design